Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04874233 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
A Phase 2 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04874233 is a Phase 2 study of NASH - Nonalcoholic Steatohepatitis that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 80 participants, below the 266-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04874233, a Phase 2 study of NASH - Nonalcoholic Steatohepatitis, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HU6
Study Locations (1)
Minnesota
- Prism Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2021-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04874233
The ClinicalTrials.gov registry entry for NCT04874233 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (70% lower). The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04874233 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04874233 about?
NCT04874233 is a clinical study titled "Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers". This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.
What is the current status of trial NCT04874233?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-04-19. Estimated completion is 2021-12-15.
What conditions does trial NCT04874233 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT04874233?
The interventions under investigation include: Placebo (DRUG), HU6 (DRUG).
Who is sponsoring clinical trial NCT04874233?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04874233 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
ACTIVE NOT RECRUITING · Phase 2
-
Statins for the Treatment of NASH
ACTIVE NOT RECRUITING · Phase 2
-
Tocotrienol Against the Progression of End Stage Liver Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.